Last updated: February 14, 2026
Product Overview
NDC 68382-0186 is a drug marketed under the brand name Vasculera, a food supplement with claimed benefits in vascular health. Its active ingredients typically include botanicals or nutrients aimed at improving blood flow or related vascular conditions.
Market Context
Vasculera operates in a niche segment of vascular health supplements, competing with both prescription drugs and over-the-counter (OTC) products targeting similar conditions such as peripheral artery disease, chronic venous insufficiency, and other circulatory issues. The segment's growth aligns with increasing awareness of vascular health and a rising elderly population prone to circulatory disorders.
Regulatory Status and Commercialization
Vasculera's classification as a dietary supplement in the U.S. impacts its regulatory pathway, marketing, and pricing strategies. It is not an FDA-approved drug but is sold as a supplement, which limits its FDA oversight to safety and labeling. It is marketed predominantly through non-prescription channels.
Market Size and Trends
The global dietary supplements market targeting vascular health was valued at approximately $10 billion in 2022[1]. Within this segment, botanical and nutraceutical products account for about 40%. Growth is driven by aging populations, increased consumer health awareness, and a preference for natural products.
In the U.S., retail sales of vascular health supplements, including Vasculera, approached $500 million annually, with a compound annual growth rate (CAGR) between 6% and 8% over the past five years. Growth is driven by direct-to-consumer marketing and increasing distribution channels.
Competitive Landscape
Key competitors include:
- Prescription drugs: Cilostazol (Pletal), for intermittent claudication.
- OTC products: Ginkgo biloba, vinegar-based supplements, herbal formulations.
- Other nutraceuticals: L-arginine, fish oil, and plant-based formulations.
Market entry of generics or similar botanical products could exert downward pressure on prices.
Pricing Analysis and Projections
| Parameter |
Current Market Price (USD) |
Notes |
| Average retail price per bottle (60 capsules) |
$25 - $45 |
Pricing varies based on retailer, formulation strength, and promotional discounts. |
| Cost of goods sold (COGS) |
Approx. $8 - $12 per bottle |
Estimated based on sourcing botanicals and manufacturing costs. |
| Gross margin |
55% - 70% |
Typical margin for dietary supplements. |
| Monthly consumption (average) |
1 bottle ($25-$45) |
For an individual maintaining a daily dose. |
Price Projections (Next 3 Years)
-
Scenario 1: Steady Growth
Price remains within the current range, with minor increases reflecting inflation and distribution costs.
Projected average retail price: $27 - $50 by 2026.
-
Scenario 2: Competitive Pressure and Generic Entry
Prices decline 10-15% due to increased competition and OTC availability.
Projected average retail price: $23 - $42 by 2026.
-
Scenario 3: Premium Branding and Formulation Innovations
Companies develop formulations with additional claimed health benefits, supporting higher price points.
Projected average retail price: $30 - $55 by 2026.
Key Price Drivers
- Regulatory changes influencing marketing claims and formulation approvals.
- Consumer demand for natural and botanical supplements.
- Entry of generic or new botanical competitors.
- Distribution expansion in digital channels and international markets.
Clinical Development and Future Outlook
No current clinical trials aim at obtaining FDA approval for Vasculera as a drug. If regulatory stances shift toward stricter controls or new clinical data emerges, potential reclassification could significantly impact market size and pricing. Conversely, continued consumer demand for natural alternatives supports steady growth in OTC sales.
Regulatory and Policy Influences
Increased regulation of dietary supplements, including stricter labeling and safety standards, could influence manufacturing costs and thus pricing. The FDA's recent emphasis on supplement safety recalls and enforcement actions under the Dietary Supplement Health and Education Act (DSHEA) in 2021-22[2] suggests a tightening regulatory environment.
Conclusion
Vasculera's market hinges on its positioning as a dietary supplement in the vascular health segment. Price stability will depend on competitive dynamics, consumer perception, and regulatory landscape adjustments.
Key Takeaways
- Vasculera competes mainly as a dietary supplement in the $10 billion global vascular health segment.
- Current retail prices average $25-$45 for a 60-capsule bottle.
- Price projections suggest minimal increases unless market conditions shift toward premium formulations or regulatory burdens.
- Competition from OTC botanicals and potential generics could pressure prices downward.
- Market growth is driven by demographic trends and a consumer shift toward natural health products.
Frequently Asked Questions
-
Could Vasculera transition into a prescription drug?
Transitioning requires FDA approval via rigorous clinical trials, which currently is not in process. Such a shift could dramatically alter its market and pricing strategies.
-
What are the main factors that could lower Vasculera's price?
Entry of generic botanical products, increased competition, and regulatory pressures could reduce retail prices by up to 15%.
-
How does regulatory status influence pricing?
As a dietary supplement, Vasculera faces fewer restrictions and can be sold OTC at lower costs. FDA regulation of drugs would elevate costs and prices.
-
Is there international market potential?
Yes, especially in regions with high demand for natural vascular health products, but regulatory differences may affect pricing models.
-
Are clinical trials likely to impact Vasculera's market?
If clinical evidence emerges supporting its efficacy and safety, it could facilitate a move toward prescription status or premium marketing, affecting prices accordingly.
References
- Market Research Future, "Vascular Health Supplements Market," 2022.
- FDA, "Dietary Supplement Enforcement," 2022.
